Alexion
NEWS
AstraZeneca’s Alexion plans to buy all remaining equity in Caelum Biosciences and pick up Caelum’s CAEL-101 in the process.
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
The FoCus Phase III trial by Alexion and AstraZeneca showed that ALXN1840 demonstrated around three times greater copper mobilization from tissues than SoC treatments for Wilson disease.
The group said that the Phase III trial of Ultomiris (ravulizumab) lacked efficacy when it was used on adults diagnosed with amyotrophic lateral sclerosis.
Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
June is turning out to be a busy month for PDUFA dates for the U.S. Food and Drug Administration. Here’s a look at this week’s dates.
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
JOBS
IN THE PRESS